Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531

被引：7

作者：

Gamis, Alan S. ^{[1
]}

Alonzo, Todd A. ^{[2
]}

Gerbing, Robert B. ^{[3
]}

Aplenc, Richard ^{[4
]}

Sung, Lillian ^{[5
]}

Meshinchi, Soheil ^{[6
]}

Raimondi, Susana C. ^{[7
]}

Hirsch, Betsy A. ^{[8
]}

Kahwash, Samir ^{[9
]}

Heerema-McKenney, Amy ^{[10
]}

Winter, Laura ^{[11
]}

Glick, Kathleen ^{[12
]}

Byron, Patti ^{[13
]}

Burden, Laura ^{[3
]}

Wallas, Tanya ^{[3
]}

Davies, Stella M. ^{[14
]}

Smith, Franklin O. ^{[15
]}

机构：

[1] Childrens Mercy Hosp & Clin, Kansas City, MO USA

[2] Univ So Calif, Keck Sch Med, Dept Prevent Med, Arcadia, CA USA

[3] Childrens Oncol Grp, Arcadia, CA USA

[4] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[5] Hosp Sick Children, Dept Pediat, Div Hem Onc, Toronto, ON M5G 1X8, Canada

[6] Fred Hutchinson Canc Rsrch Ctr, Seattle, WA USA

[7] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA

[8] Univ Minnesota, Div Lab Med, Med Ctr Fairview, Minneapolis, MN USA

[9] Nationwide Childrens Hosp, Columbus, OH USA

[10] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[11] Seattle Childrens Hosp, Seattle, WA USA

[12] Maine Childrens Canc Program, Scarborough, ME USA

[13] British Columbia Childrens Hosp, Vancouver, BC V6H 3V4, Canada

[14] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA

[15] Childrens Hosp, Med Ctr, Div Hematol & Oncol, Cincinnati, OH 45229 USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.182.182

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：83 / 84

页数：2

共 26 条

[21] Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups
Amadori, Sergio
Suciu, Stefan
Selleslag, Dominik
Rossetti, Elena
Gaidano, Gianluca
Musso, Maurizio
Annino, Luciana
Venditti, Adriano
Magro, Domenico
de Fabritiis, Paolo
Muus, Petra
Alimena, Giuliana
Mancini, Marco
Hagemeijer, Anne
Cotugno, Francesca
Vignetti, Marco
Fazi, Paola
Meert, Liv
Ramadan, Safaa M.
Willemze, Roelof
de Witte, Theo
Baron, Frederic
BLOOD, 2014, 124 (21)
[22] Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631
Kutny, Matthew A.
Alonzo, Todd A.
Gerbing, Robert B.
Wang, Yi-Cheng
Raimondi, Susana C.
Hirsch, Betsy A.
Fu, Cecilia H.
Meshinchi, Soheil
Gamis, Alan S.
Feusner, James H.
Gregory, John J., Jr.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) : 3021 - +
[23] Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia
Petersdorf, Stephen
Kopecky, Kenneth
Stuart, Robert K.
Larson, Richard A.
Nevill, Thomas J.
Stenke, Leif
Slovak, Marilyn L.
Tallman, Martin S.
Willman, Cheryl L.
Erba, Harry
Appelbaum, Frederick R.
BLOOD, 2009, 114 (22) : 326 - 327
[24] LOW DOSE GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS. INTERIM RESULTS FROM A PHASE III MULTICENTER PROSPECTIVE CLINICAL TRIAL (MYFLAI07NCT.00909168).
Candoni, A.
Martinelli, G.
Gherlinzoni, F.
Papayanidis, C.
Lacobucci, I.
Gottardi, M.
Visani, G.
Simeone, E.
Paolini, S.
Lama, B.
Michelutti, A.
Isidori, A.
Piccaluga, P.
Sparaventi, G.
Malagola, M.
Russo, D.
Baccarani, M.
Fanin, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 225 - 225
[25] Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial
van Dijk, Anneke D.
Ruvolo, Peter P.
Hoff, Fieke W.
Qiu, Yihua
Gamis, Alan S.
Aplenc, Richard
Kolb, Anders E.
Alonzo, Todd A.
Gerbing, Robert B.
de Bont, Eveline S.
Bruggeman, Sophia W. M.
Horton, Terzah M.
Kornblau, Steven M.
BLOOD, 2019, 134
[26] Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II-III Randomized Trial (JPLSG AML-12)
Tomizawa, Daisuke
Tanaka, Shiro
Hasegawa, Daisuke
Iwamoto, Shotaro
Hiramatsu, Hidefumi
Kiyokawa, Nobutaka
Miyachi, Hayato
Horibe, Keizo
Saito, Akiko Moriya
Taga, Takashi
Adachi, Souichi
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (06) : 587 - 593

← 1 2 3 →